DFE Pharma, a global leader in pharmaceutical excipients, has launched its Continuous Manufacturing (CM) platform, designed to support pharmaceutical companies in formulation development, optimization, and lifecycle management of CM processes.

In collaboration with Gericke, this initiative combines CM-ready excipients, flexible CM evaluation environment, and multidisciplinary expertise, enabling data-driven decisions from early exploration through optimization and long-term operation of CM.

As part of the CM platform, DFE Pharma has invested in continuous manufacturing capability at its C2F Center of Excellence in Hyderabad, India, featuring a Gericke Formulation Skid (GFS). This formulation skid, with modular feeding and blending options, is placed in a non-GMP environment, enabling fast iterations and practical assessment and optimization without disrupting existing GMP manufacturing or requiring upfront infrastructure investment.

The modular setup at the C2F Center supports flexible process and formulations testing by combining the GFS with pre-blending and downstream process and analytical capabilities to generate decision-relevant insights. This equipment gives pharmaceutical companies the opportunity to experience how continuous feeding and blending operate in practice, test formulation strategies using CM-ready materials, and learn how evaluation data translates directly into real world implementation.

“Continuous Manufacturing is reshaping how medicines are developed and produced, but success depends on making the right choices at every stage,” said Dr. Sven Abend, CEO, DFE Pharma. “With our Continuous Manufacturing platform, we are bringing together our CM-ready excipients, a flexible testing environment, and applied scientific expertise. We are sure this platform will enable our customers to make informed, data-driven CM decisions from early exploration through optimization and long-term operation with confidence.”

“At Gericke, we contribute decades of engineering and process knowledge, helping customers interpret CM data, understand material–equipment interactions, optimize key parameters, and align their strategies with guidelines such as ICH Q13. Together, we provide clear, science-based direction that supports a smooth transition to robust Continuous Manufacturing,” explained Markus Gericke, CEO at Gericke Group.